PUBLICATIONS ALERT: Three articles focused on optimizing treatment strategies for multidrug-resistant tuberculosis (MDR-TB)

• Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
• Efficacy and Safety of Higher Doses of Levofloxacin for MDR-TB: A Randomized Placebo-controlled Phase 2 Trial
• Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial

View all posts